Seeking Alpha
22 Oct 2026, 19:47 UTC · 1h ago
Xvivo Perfusion AB (publ) (XVIPY) Q3 2026 Earnings Call Transcript
Impact · against what's priced in
Xvivo Perfusion shows strong operational momentum with 32% organic growth and a stabilized cash position. The transition to a self-sustaining burn rate reduces dilution risk and establishes a higher revenue baseline for future growth.
- XVIPY+0.60
No priced-in read yet
- In context
The company achieved 32% organic growth in Q3 2026 and maintained a neutral total cash flow for the fourth consecutive quarter, indicating it has reached a self-sustaining burn rate.
Read from the article alone
Top 2 movers · tap to explore
